AUS
NZ
UK
CA
USA
IND
Highlights:
Upcoming Earnings Announcement: Pfizer Inc. is scheduled to report its fiscal Q3 earnings results on Tuesday, October 29, with analysts projecting a profit of $0.62 per share, a significant turnaround from a loss in the same quarter last year.
Positive Performance Trends: The biopharmaceutical company has consistently outperformed Wall Street's bottom-line estimates in the last four quarters, attributing its success to cost-cutting measures and increased sales of its COVID-19 antiviral pill, Paxlovid.
Mixed Stock Performance: Pfizer shares have gained 3% year-to-date, trailing behind the S&P 500 Index and the Health Care Select Sector SPDR Fund, which have posted gains of 22.4% and 13%, respectively.
Pfizer Inc. (NYSE:PFE), valued at a market capitalization of $164.8 billion, is a leading biopharmaceutical company engaged in the discovery, manufacturing, distribution, and marketing of medicines and vaccines across various therapeutic areas, including immunology, oncology, cardiology, endocrinology, and neurology. The company is particularly known for its Pfizer–BioNTech COVID-19 vaccine. The firm is anticipated to announce its fiscal Q3 earnings results before the market opens on October 29.
Analysts project that Pfizer will report earnings of $0.62 per share, marking an impressive increase of 464.7% from a loss of $0.17 per share in the prior year’s quarter. The company has consistently exceeded Wall Street's expectations, having reported an EPS of $0.60 in Q2, surpassing consensus estimates by 33.3%. This strong performance is attributed to effective cost-cutting initiatives, robust sales of the COVID-19 antiviral treatment Paxlovid, and solid performance in its non-COVID medication portfolio.
For fiscal 2024, analysts anticipate an EPS of $2.66, reflecting a year-over-year growth of 44.6% from $1.84 in fiscal 2023.
Despite these positive developments, Pfizer's stock has gained only 3% year-to-date, significantly underperforming both the S&P 500 Index and the Health Care Select Sector SPDR Fund, which have registered increases of 22.4% and 13%, respectively.
On October 10, shares of Pfizer fell by 2.8% following accusations from activist investor Starboard Value, which claimed that Pfizer had attempted to coerce two former executives into retracting their support for Starboard's initiatives. Following Starboard's acquisition of a substantial stake in Pfizer on October 7, there were initial signs of investor optimism regarding potential corporate improvements.
As of now, analysts maintain a moderately optimistic view of Pfizer's stock, with a consensus rating classified as "Moderate Buy." Among the 21 analysts covering the stock, nine recommend a "Strong Buy," while 12 suggest a "Hold." This configuration reflects a slight increase in bullish sentiment compared to three months prior, with an average analyst price projection of $33.10, indicating a potential upside from current levels.
